The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

doi:10.18632/oncotarget.5718

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

Oncotarget - 1 Mar 2016

Terragna Carolina, Remondini Daniel, Martello Marina, Zamagni Elena, Pantani Lucia, Patriarca Francesca, Pezzi Annalisa, Levi Giuseppe, Offidani Massimo, Proserpio Ilaria, De Sabbata Giovanni, Tacchetti Paola, Cangialosi Clotilde, Ciambelli Fabrizio, Viganò Clara Virginia, Dico Flores Angela, Santacroce Barbara, Borsi Enrica, Brioli Annamaria, Marzocchi Giulia, Castellani Gastone, Martinelli Giovanni, Palumbo Antonio, Cavo Michele

Abstract excerpt

The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is to obtain an early and deep tumour burden reduction, up to the level of complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study aimed at the molecular characterization of PC obtained at baseline from MM patients in CR after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Bortezomib

Share to Dexamethasone

Share to Disease-Free Survival

Share to Induction Chemotherapy

Share to Multiple Myeloma

Share to Remission Induction

Share to Thalidomide

Source

Open in PubMed Open full text

Identifiers

PMID: 26575327
DOI: 10.18632/oncotarget.5718
PMCID: PMC4891075

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).PMID 26575327Read ↗

Multi-omics analysis of multiple myeloma patients with differential response to first-line treatment.Semantic proximity Read ↗

Risk Stratification and Targets in Multiple Myeloma: From Genomics to the BedsideSemantic proximity Read ↗

Functional Impact of Genomic Complexity on the Transcriptome of Multiple MyelomaSemantic proximity Read ↗

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.Semantic proximity Read ↗

Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomicsSemantic proximity Read ↗

Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.Semantic proximity Read ↗

DNA damage repair (DDR) related prognostic risk model in multiple myeloma based on single-cell and bulk sequencing.Semantic proximity Read ↗

Genomic characterization of functional high-risk multiple myeloma patients.Semantic proximity Read ↗

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patientsSemantic proximity Read ↗

Integrative multi-omics identifies high risk Multiple Myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathwaysSemantic proximity Read ↗

Single cell RNA-seq data and bulk gene profiles reveal a novel signature of disease progression in multiple myelomaSemantic proximity Read ↗

Transcriptional signature of TP53 biallelic inactivation identifies a group of multiple myeloma patients without this genetic condition but with dismal outcome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.